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Abstract
Numerous mitochondrial DNA mutations cause mitochondrial encephalomyopathy: a collection of related diseases for
which there exists no effective treatment. Mitochondrial encephalomyopathies are complex multisystem diseases that
exhibit a relentless progression of severity, making them both difficult to treat and study. The pathogenic and
compensatory metabolic changes that are associated with chronic mitochondrial dysfunction are not well understood. The
Drosophila ATP6
1 mutant models human mitochondrial encephalomyopathy and allows the study of metabolic changes and
compensation that occur throughout the lifetime of an affected animal. ATP6
1animals have a nearly complete loss of ATP
synthase activity and an acute bioenergetic deficit when they are asymptomatic, but surprisingly we discovered no chronic
bioenergetic deficit in these animals during their symptomatic period. Our data demonstrate dynamic metabolic
compensatory mechanisms that sustain normal energy availability and activity despite chronic mitochondrial complex V
dysfunction resulting from an endogenous mutation in the mitochondrial DNA. ATP6
1animals compensate for their loss of
oxidative phosphorylation through increases in glycolytic flux, ketogenesis and Kreb’s cycle activity early during
pathogenesis. However, succinate dehydrogenase activity is reduced and mitochondrial supercomplex formation is severely
disrupted contributing to the pathogenesis seen in ATP6
1 animals. These studies demonstrate the dynamic nature of
metabolic compensatory mechanisms and emphasize the need for time course studies in tractable animal systems to
elucidate disease pathogenesis and novel therapeutic avenues.
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Introduction
Normal metabolic pathways in animals have been elucidated
and extensively studied for decades; however, the response of each
pathway to the loss or disturbance of another is poorly understood.
The eukaryotic cell and its mitochondria have evolved different
methods of energy production from the catabolism of most food
products. However, there are many human diseases that disrupt,
typically via genetic hypomorphic mutations, one of these
pathways. Such heritable diseases known collectively as inborn
errors of metabolism do not immediately cause death; they do,
however, lead to poorly understood diseases including enzymo-
pathies and mitochondrial encephalomyopathies. Metabolic
pathways are complex networks, therefore a single perturbation
resulting from a single gene mutation can lead to dramatic changes
in an animal’s ability to maintain its normal physiological
functions as well as homeostatic impairment that affects its ability
to cope with environmental stresses [1].
Our current understanding of mitochondrial disease has been
facilitated by the study of cellular cybrids bearing human disease
mutations. However, such systems have not yielded a clear picture
of the bioenergeticsand compensatory mechanisms that exist within
the tissues of an intact animal with mitochondrial disease. Thus, no
comprehensible understanding of the associated pathogenesis has
resulted, demonstrating the inherent difficulty in using cellular
models to study multisystem diseases [2,3]. Additionally, these
diseases typically exhibit an asymptomatic period varying from days
to decades, onset, and a stereotyped progression of the disease
making them difficult to model in cellular systems. Little is known
about disease pathogenesis in an intact animal with functional
neurons and muscle fibers that can be examined over the life of the
animal. Thus, it is essential to study the progressive nature and
tissue-specific attributes of these diseases with the goal of identifying
endogenous compensatory mechanisms that might be exploited as
therapeutic avenues.
Here we utilize a novel, well-characterized, endogenous
mitochondrial mutation in the ATP6 gene (NC_001709.1) of
Drosophila melanogaster with a nearly complete loss of ATP synthase
activity [4]. These Drosophila mutants have a missense mutation in
ATP6 (G to A transition resulting in a glycine to glutamate change
at position 116 in the protein), the mitochondrial gene encoding
subunit 6 of the F1Fo-ATP synthase (complex V of the respiratory
chain) [4,5,6,7,8]. ATP6 allows for the hydrogen ion translocation
required for the rotation of the Fo motor and the production of
ATP from ADP [9]. Drosophila ATP6
1 mutants model human
mitochondrial encephalomyopathy and demonstrate phenotypes
associated with degenerative disease, including: reduced longevity,
mitochondrial pathology, progressive neural dysfunction, tissue
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and two frame shift mutations lead to ATP6 impairment and are
known to cause the related mitochondrial disorders: maternally
inherited Leigh’s syndrome (MILS), neuropathy, ataxia, and
retinitis pigmentosa (NARP), and familial bilateral striatal necrosis
(FBSN) [10,11,12,13,14,15,16,17,18]. These diseases are charac-
terized by reduced longevity, progressive neuromuscular impair-
ment, seizures, myodegeneration and a range of devastating
complications resulting from renal, cardiac, endocrine and hepatic
system dysfunction [19,20,21,22,23,24,25,26,27,28]. The diversity
of symptoms and phenotypes associated with ATP6 dysfunction in
humans and flies likely reflects this protein’s important and highly
conserved role in cellular bioenergetics. The pathological basis of
diseases associated with ATP6 impairment in humans is not
understood but it has been hypothesized that there may be
uncoupling of complex V resulting in bioenergetic impairment and
oxidative stress owing to respiratory chain dysfunction [29,30].
Our results demonstrate that there are dynamic adjustments
made within many of the metabolic pathways over the lifetime of
animals with ATP6 dysfunction, which allow them to maintain a
normal level of energy, despite the severe reduction in ATP
production through oxidative phosphorylation (OXPHOS). Gly-
colysis and ketogenesis compensate for the OXPHOS defect
earlier in life. We also demonstrate that a loss in mitochondrial
supercomplex formation and complex II activity are associated
with pathogenesis. These data demonstrate that mitochondrial
encephalomyopathies results in dynamic metabolic compensation
and that disease pathogenesis does not result from a loss of energy
and involves a cascade of events broadly affecting metabolic and
mitochondrial function.
Results
ATP6
1 survival and behavioral changes
ATP6
1 Drosophila mutants exhibit a stereotyped phenotypic
progression that is analogous to the symptomatic progression
reported for many human mitochondrial disease patients [5,14].
ATP6
1 mutant flies demonstrate stress sensitivity, shortened
lifespan, muscle degeneration and abnormal mitochondrial
morphology [4]. ATP6
1 animals eclose looking and acting
completely normal and are morphologically and behaviorally
indistinguishable from wildtype animals. ATP6
1 animals exhibit a
stereotypical progression of disease following onset (,day 8) when
the animals begin to have reduced locomotor activity (Figure 1A
and 1B). By day 13, ATP6
1 animals are sensitive to mechanical
stress resulting in paralysis, suggesting neuromuscular impairment.
At ,day 20, ATP6
1 animals can be observed having sporadic and
unprovoked seizure-like activity. Late in pathogenesis ATP6
1
phenotypes continue to worsen until their premature death
(Figure 1B).
We discovered that ATP6
1 animals have a similar developmen-
tal survival rate as wildtype animals whether they are raised at
22uCo r2 9 uC (Figure 1C). Interestingly, ATP6
1 animals show a
modest but significant shortening in the time of development
during the larval and pupal stages at 22uC and during the larval
stage at 29uC (Figure 1D). Additionally, ATP6
1 females lay
significantly more eggs than wildtype animals during their first
week of life (Figure 1E). These data demonstrate that the altered
physiology of ATP6
1 animals results in an accelerated development
and increase in female fecundity. Such effects could cause increase
utilization of energy early in life to ensure survival despite the
dramatically altered physiology.
To examine the seizure behavior we asked whether sensory
hyperstimulation, such as a strobe light, could elicit seizure
behavior in ATP6
1 flies. Video analysis of locomotor function prior
to, during, and following 1450 fpm (flashes per minute) strobe
lighting (20 seconds) was used to examine the ability to induce
seizure behavior by sensory hyperstimulation alone. Although
strobe lighting did not affect the locomotion of wildtype flies
(Video S1, Video S2, Video S3), ATP6
1 animals exhibited
convulsive behavior with a high penetrance both during and after
the strobe light (Video S4, Video S5, Video S6). Surprisingly, the
convulsive behavior was followed by full paralysis that continued
well after resumption of normal lighting (Figure 1F, Video S6).
This phenotype was also progressive, as young animals did not
exhibit convulsions or paralysis (Figure 1F).
Energy buffering capacity and energy levels over time in
ATP6
1 animals
We examined the effect altered ATP6
1 physiology had on
animal bioenergetics. We examined phosphoarginine (P-Arg),
arginine (Arg) as well as the adenylate pool using distinct HPLC
protocols (Figure 2). P-Arg is the invertebrate equivalent to
phosphocreatine, which buffers ATP levels and provides a
reliable measure of bioenergetics [31]. Since we observe
progressive pathogenesis in ATP6
1 animals, we analyzed the
bioenergetic state over a relevant time course from asymptom-
atic to late-stage pathogenesis. Wildtype animals exhibit a
reduction in P-Arg:Arg ratios over the first two weeks of their
adult life that appear to plateau around 0.18 (Figure 2A).
Surprisingly, ATP6
1 animals also plateau at ,0.18 when aged,
however, in the first week of their adult life P-Arg:Arg ratios are
significantly reduced from that of age-matched wildtype control
animals (Figure 2A).
We also examined the adenylate pool (ATP, ADP and AMP)
from mutant and control animals using the same time course and
the identical trend was observed (Figure 2B). A surprising decrease
in the ATP:ADP ratio can be seen at days 3 and 6 (when mutants
are largely aphenotypic) but no change was noted at later time
points when the phenotypes are marked in severity. These data are
in agreement with the data from the P-Arg:Arg assays. We also
noted an age dependent decrease in AMP unique to ATP6
1
animals (day 20; Figure 2C). However, no change in overall total
adenylate pool was noted (data not shown). These data
surprisingly demonstrate that bioenergetic impairment is not likely
to cause pathogenesis and suggests the importance of compensa-
tory metabolic pathways in delaying disease pathogenesis.
Metabolic compensation: glycolysis
Substrate level phosphorylation occurs in glycolysis when
phosphoenol pyruvate is converted to pyruvate and in the Kreb’s
cycle when succinyl-CoA is converted to succinate. It is thus
predicted that without a functional ATP synthase (Complex V), 2
net ATP per glucose are produced through glycolysis and 1 GTP
per acetyl-CoA can be produced through the Kreb’s cycle.
Additionally, it has been demonstrated in cell cybrid models that
defects in respiratory chain complexes leads to an upregulation of
glycolysis [32]. Using steady state lactic acid as a measure of
glycolytic flux, a dramatic increase can be seen in young ATP6
1
animals (day 5) compared to age matched controls (Figure 3).
Later in life (days 10 and 20) these levels have dropped to wildtype
levels. These data demonstrate that increased glycolysis is an
important early compensatory mechanism that is ineffective at
fully abating the reduced bioenergetics observed prior to
pathogenesis. These data also imply that lactic acidosis is not
likely to account for the severe pathogenesis observed late in life
(,days 15–25).
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1 animals. A) Longevity curve showing wildtype (green) and ATP6
1 (red) demonstrating an ,40%
reduction in lifespan. Green, yellow and orange shading describes the change in animal behavior over ATP6
1 lifespan. Life spans are based upon 80
total animals per genotype. Error is S.E.M. Statistical analysis is log-rank. B) Summary of phenotypic progression of ATP6
1 animals. C) Graph showing
normal developmental survival rate for ATP6
1 compared to wildtype at 22uC and 29uC. N=510 ATP6
1 at 22uC, N=173 wildtype at 22uC, N=696 ATP6
1
at 29uC, N=586 wildtype at 29uC. Error is S.E.M. Statistical analysis is student’s t-test. D) ATP6
1 mutants develop significantly faster than controls at
22uC (to eclosion) and at 29uC (to pupation). N=30 both genotypes both temperatures. Error is S.E.M. Statistical analysis is student’s t-test. E) ATP6
1
animals exhibit a higher fecundity early in adulthood. Gray represents dark intervals of a 12:12 light dark regime. N=462 ATP6
1 , N=139 wildtype.
Error is S.E.M. Statistical analysis is student’s t-test. F) Strobe lighting induces seizure-like convulsions followed by paralysis only in aged ATP6
1
animals. Young mutants and controls did not exhibit convulsions or paralysis. ATP6
1 day 5 N=17; day 13 N=19; day 20 N=13; day 25 N=23.
Wildtype day 5 N=14; day 13 N=23; day 20 N=13; day 25 N=25. Error is S.E.M. Statistical analysis at day 25 is a two-tailed Mann-Whitney U test. Also
see S1A–C and S2A–C.
doi:10.1371/journal.pone.0025823.g001
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Ketogenesis. When animals are metabolically stressed, such
as during starvation, they transition to utilizing fatty acids through
beta-oxidation and ketogenesis. We investigated the hypothesis
that ATP6
1 animals are utilizing ketogenesis to compensate for
OXPHOS impairment. Ketogenesis is a multi-step pathway that
converts acetyl-CoA to ketone bodies (acetoacetate, acetone and
beta-hydroxybutyrate) that can be utilized by numerous tissues in
the body, including the brain, to produce energy (Figure 4A). The
expressions of two key enzymes, involved in ketogenesis, were
measured over the life of ATP6
1 animals to determine the
likelihood that this pathway is up-regulated. Both thiolase and 3-
hydroxy-3-methylglutaryl-CoA synthase (HMGS) are up-
regulated in ATP6
1 animals compared to wildtype animals
beginning at day 13 (Figure 4B and 4C, respectively).
Additionally, elevated beta-hydroxybutyrate was observed in
ATP6
1 animals versus control animals early in adult life
(Figure 4D). However, the ,6-fold increase in steady state beta-
hydroxybutyrate levels seen in young mutants are not maintained
as ATP6
1 animals age and there is a reduction compared to
wildtype by day 20, a time coincident with a marked worsening of
ATP6
1 phenotypes (Figure 4D).
To understand whether this decrease in beta-hydroxybutyrate
was due to the inability to maintain elevated ketone bodies or an
increase in catabolism, 3-oxoacid-CoA transferase was measured.
This enzyme is involved in ketone body catabolism converts of
succinyl-CoA and acteoacetate (a ketone body) to succinate and
acetoacetyl-CoA (Figure 4E). The expression level of this enzyme,
in ATP6
1 animals, shows an ,2.5-fold increase in expression
compared to wildtype at days 13 and 20 (Figure 4F). These data
suggest that both synthesis and catabolism are increased and that
catabolism must be increased relative to synthesis to produce lower
steady state beta-hydroxybutyrate levels.
Figure 2. Bioenergetics of wildtype and ATP6
1 animals. A) P-
Arg:Arg ratiosexhibit impairedbioenergticsinATP6
1 animals onlyatadult
day 3 and 6 compared to age-matched wildtype. All mutant genotypes
are mt ATP6
1,s e s B
1/+ and wildtype controls are mt ATP6
+, sesB/+.s e s B
1
(recessive stress sensitive B mutation) is the fly homologue to ANT
(adenine nucleotide translocase) and ATP6
1 is maintained in this mutant
background and the heteroplasmy is verified by RFLP analysis prior to
experimentation (Data not shown). F1 female progeny heterozygous for
sesB
1 are of high mutant heteroplasmy and were analyzed compared to
sesB
1 heterozygote controls. N=9 wildtype at each time point, N=6
ATP6
1 day 3 and 13, N=9 ATP6
1 day 6 and 20. Error is S.E.M. Statistical
analysis is student’s t-test. B) The ATP:ADP ratio analyses show a similar
reduction in bioenergetics only in young mutants. N=9 wildtype at each
time point, N=6 ATP6
1 day 3 and 13, N=9 ATP6
1 day 6 and 20. Error is
S.E.M. Statistical analysis is student’s t-test. C) Comparison of uM AMP per
mg of tissue between wildtype and ATP6
1 animals show a modest
decrease in AMP in aged mutants at day 20. No significant changes are
seen in total adenylate pool in ATP6
1 animals. N=9 wildtype at each time
point, N=6 ATP6
1 day 3 and 13, N=9 ATP6
1 day 6 and 20. Error is S.E.M.
Statistical analysis is student’s t-test.
doi:10.1371/journal.pone.0025823.g002
Figure 3. Glycolytic compensation in young ATP6
1 animals. A
significant increase in lactic acid levels is seen in ATP6
1 animals on day 5
compared to wildtype animals. Steady state lactic acid is unchanged
between wildtype and mutants at day 10 and 20. N=9 wildtype at each
time point, N=9 ATP6
1 day 5 and 10, N=6 ATP6
1 day 20. Error is S.E.M.
Statistical analysis is student’s t-test.
doi:10.1371/journal.pone.0025823.g003
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1 and wildtype animals
over lifespan
During OXPHOS, oxygen is the final acceptor of electrons that
are passed across the inner mitochondrial membrane at complex
IV and is ultimately reduced to water. CO2 is produced during the
transition from glycolysis to the Kreb’s cycle where pyruvate
dehydrogenase converts pyruvate to acetyl-CoA and within the
Kreb’s cycle at the conversion of isocitrate to alpha-ketoglutarate
Figure 4. Ketogenic compensation in ATP6
1 animals. A) The ketogenic metabolic pathway is used to produce ketone bodies (acetoacetate,
acetone and beta-hydroxybutyrate). Enzymes shown in red. B & C) Real-time quantitative RT-PCR of the enzyme thiolase and 3-hydroxy-3-methyl-
glutaryl-CoA synthase (HMGS) reveal an increasing trend in ATP6
1 animals with age compared to wildtype. N=12 wildtype each time point. N=12
ATP6
1 each time point. Error is S.E.M. Statistical analysis is student’s t-test. D) Quantitation of beta-hydroxybutyrate shows a marked increase in young
animals with a decreasing trend with age compared with wildype. N=9 wildtype day1–2, N=5 wildtype days 13 and 20. N=6 ATP6
1 day 1–2, N=5
ATP6
1 days 13 and 20. Error is S.E.M. Statistical analysis is student’s t-test. E) The enzyme 3-oxoacid-CoA transferase is involved in ketone body
catabolism. F) Real-time quantitative RT-PCR of 3-oxoacid-CoA transferase reveals an increasing trend with age in ATP6
1 animals versus controls.
N=12 wildtype each time point. N=12 ATP6
1 each time point. Error is S.E.M. Statistical analysis is student’s t-test.
doi:10.1371/journal.pone.0025823.g004
ATP6 Dysfunction and Metabolic Compensation
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Respiration is typically intimately coupled to mitochondrial energy
production and ATP6
1 are severely deficient in OXPHOS,
suggesting respiration would be a key parameter to understand
bioenergetics and pathogenesis resulting from ATP6 impairment.
To determine whether there is an age-specific change in metabolic
rate, we assayed rates of CO2 production in wildtype and ATP6
1
flies.
Respiration rate was measured in individual animals at days 5,
10, 15 and 20 as the emergence of CO2 (Figure 5A and 5B). A
natural trend emerged in wildtype animals, where the respiration
rate increased over time plateauing between days 15–20. These
data demonstrate a normal change in respiration and metabolic
physiology associated with aging in our wildtype strain. Interest-
ingly, ATP6
1 animals also exhibit a similar trend, however, the
increase observed through day 15 dramatically reverses by day 20
(Figure 5A). By examining the single animal data the trend of
increasing at day 15 and the dramatic reduction observed by day
20 for most animals can be clearly seen with only a few outliers
(Figure 5B). These data demonstrate that ATP6
1 animals exhibit
modestly elevated respiration during the aphenotypic period, and
that onset of pathogenesis is associated with a striking increase in
respiration followed by a dramatic drop in respiration corre-
sponding to severe phenotypic impairment.
The dynamic changes observed in metabolic physiology and
respiration over time could also be mediated through changes in
mitochondrial metabolic substrate utilization. An estimate of
substrate use can be obtained by comparing the ratio of CO2
produced during respiration to the amount of O2 consumed. This
ratio termed the respiratory quotient (RQ) varies from approxi-
mately 0.7 for pure lipid metabolism to 1.0 for mitochondrial
carbohydrate metabolism [33]. We determined the RQ for 5, 10
and 20 day old animals (Figure 5C). The RQ values for wildtype
and ATP6
1 animals were between 0.8 and 1.0 indicative of a
largely carbohydrate based metabolism. However, young ATP6
1
animals’ exhibit a lower RQ value consistent with an increased
usage of fatty acids. Overall, these respiration and RQ data suggest
that ATP6
1 animals may be increasing their utilization of the
Kreb’s cycle and thus producing modestly more CO2.
Kreb’s Cycle compensation in ATP6
1 animals
To test the hypothesis that the Kreb’s cycle activity has
increased in ATP6
1 animals, aconitase and succinate dehydroge-
nase (complex II) were measured. Aconitase converts citrate to
isocitrate and succinate dehydrogenase converts succinate to
fumarate after GTP production in the Kreb’s cycle (Figure 6A).
Aconitase activity is significantly increased in ATP6
1 mutant
mitochondria compared to wildtype (Figure 6B). However,
succinate dehydrogenase activity is decreased in ATP6
1 mito-
chondria compared to wildtype (Figure 6C). These data suggest
that ATP6
1 animals may be attempting to increase their
utilization of the Kreb’s cycle to maintain elevated energy levels
as is seen with an increase in the aconitase step; however, later
steps (succinate dehydrogenase) are unable to keep up a wildtype
level of activity.
Complex V instability and loss of Supercomplex
formation in ATP6
1 mitochondria
TEM tomography of ATP6
1 mitochondria demonstrated a
vesicular inner mitochondrial membrane appearance lacking the
normal flattened cristae morphology seen in wildtype mitochon-
dria [4]. Using blue-native gel electrophoresis and western blot
analysis, we found impairment in complex V dimerization in
ATP6
1 animals (Figure 7A and 7C). These data imply that mutant
ATP6 protein is being expressed, yet only a small fraction of the
complex V is able to dimerize. Amazingly, this mutation also leads
to the disruption of complex I containing supercomplexes
(Figure 7B and 7C). The changes observed in complex I
supercomplexes suggest a functional connection between complex
I and V, that has not previously been appreciated and may also
explain the observed decrease in complex II activity in ATP6
1
animals.
Discussion
Mitochondrial encephalomyopathies are devastating diseases
that are difficult to diagnose and treat. Mitochondrial dysfunction
results directly from mutations in the proteins involved in
mitochondrial function, such as components required for OX-
PHOS, as is the case for archetypal mitochondrial diseases.
Numerous other common disorders such as Alzheimer’s disease,
diabetes, cardiovascular disease, obesity and premature aging
have also been associated with mitochondrial dysfunction
[34,35,36,37,38,39,40,41]. Understanding metabolic compensatory
mechanisms that occur during chronic mitochondrial dysfunction
will be needed to fully understand pathogenesis and develop
effective treatments for these disorders. Utilizing an amenable intact
animal model of mitochondrial encephalomyopathy has allowed for
thestudy ofdisease progression anda more complete understanding
of the associated pathogenesis.
The ATP6
1 pathogenic phenotypes are not due to bioenergetic
crisis. P-Arg:Arg ratios, as well as ATP:ADP ratios, show a
significant decrease compared to wildtype animals during ATP6
1
animals’ first week of life. However, these lower levels are during a
time when ATP6
1 animals do not exhibit signs of mitochondrial
pathogenesis. When ATP6
1 animals begin to exhibit locomotor
phenotypes as well as later in pathogenesis, energy levels are
maintained at normal levels. These data demonstrate that
bioenergetic crisis does not underlie pathogenesis.
The phenotypic progression in ATP6
1 animals includes: reduced
locomotor function, sensitivity to mechanical stress, unprovoked
seizure behavior, and light-induced convulsions that result in
paralysis. Seizure behavior and induced convulsions demonstrates,
in this invertebrate model, a neurological link between mitochon-
drial dysfunction and seizure activity that is also commonly seen in
mitochondrial disease patients [42,43,44]. Conditional paralysis
associated with bang- or stress-sensitivity was originally reported
many decades ago and this phenotype has remained mysterious
and controversial [45]. Our data demonstrate that sensory
hyperstimulation alone is sufficient to cause paralysis in this
bang-sensitive mutant and that this stimulation causes convulsive
seizure behavior that leads to the observed paralysis.
ATP6
1 animals compensate for their reduced ability to produce
ATP through OXPHOS by increasing their usage of other
metabolic pathways (Figure 8). The pathogenesis seen in ATP6
1
animals does not appear when the activity of the ketogenic and
glycolytic pathways remain elevated, suggesting their ability to
effectively compensate for the OXPHOS dysfunction. It is likely
that pathogenesis results from an inability to maintain these
compensatory mechanisms chronically or that chronic compensa-
tion is toxic. Further studies will be needed to distinguish between
these possibilities.
Respiration has previously been measured over the lifespan of
several wildtype organisms resulting in conflicting reports on
metabolic rate changes with age [46,47,48,49,50]. We have
found wildtype animals demonstrate an increase in respiration
early in life that plateaus as they age. ATP6
1 animals exhibit an
early increase in CO2 production during the first 2 weeks of their
ATP6 Dysfunction and Metabolic Compensation
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by a drastic reduction by day 20. This suggests that these animals
are trying to increase their utilization of the Kreb’s cycle early in
their life; however they may be unable to maintain this level of
activity later in life. Additionally, ATP6
1 animals have a lower RQ
value at day 5 and a similar value to wildtype throughout the rest of
their life. This decrease in RQ value at day 5 is consistent with the
observed increase in utilization of ketogenesis, a lipid-utilizing
pathway.
The aberrant mitochondrial morphology seen in these ATP6
1
animals can be attributed to the lack of complex V dimerization.
Recent work demonstrates that complex V dimer formation is
necessary for the bending of the inner mitochondrial membrane
giving cristae their characteristic elongated appearance and
placing complex V in the proper position to utilize the highest
concentration of hydrogen ions for catalysis [2,51,52,53,54,55,56].
The loss of efficient ATP synthase activity is either due to the
inability of complex V to dimerize or due to the malformed cristae,
which need to be elongated to concentrate the hydrogen ions for
proper ATP synthesis. Additionally, we show that this single
missense mutation disrupts the formation of supercomplexes
containing complex I. This loss of supercomplex formation may
have a causal relationship to the decrease in succinate dehydro-
genase (complex II) activity observed, thus preventing the Kreb’s
cycle from functioning at an increased level.
In conclusion, we have studied the metabolic pathways within
ATP6
1 animals and discovered a dynamic interplay between
compensatory mechanisms that results when efficient production
of ATP through OXPHOS is not possible. These compensatory
responses allow the animal to maintain largely normal levels of
ATP, demonstrating that bioenergetic crisis does not underlie
pathogenesis. This normal level of ATP may be at the expense of
the animals’ normal activity level during the second half of their
lives and thus may contribute to the observed locomotor
phenotypes. Importantly, nearly every parameter examined was
dynamic over the lifespan of ATP6
1 animals, underscoring the
importance of studying such diseases as a time course in an intact
animal model.
Figure 5. Respiration and respiratory quotient (RQ) changes over lifespan. A) Average respiration rate (ul C02/mg-hr) in wildtype (green)
and ATP6
1 (red) animals over time. On days 5, 10 and 15 ATP6
1 animals have a modest but significantly higher respiration rate than wildtype animals;
however, by day 20 ATP6
1 mutants show a significant decrease in respiration rate. N=21224 animals per time point per genotype. Error is S.E.M.
Statistical analysis is student’s t-test. B) Individual animal respiration rates at days 15 and 20. C) Respiratory quotient (RQ) of wildtype and ATP6
1
animals. There is a modest but significant, decrease of the RQ of ATP6
1 animals at day 5 compared to wildtype. N=629 chambers per time point per
genotype. Error is S.E.M. Statistical analysis is student’s t-test.
doi:10.1371/journal.pone.0025823.g005
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e25823Figure 6. Succinate dehydrogenase and aconitase enzyme activity measurements. A) Kreb’s cycle pathway; intermediates shown in boxes,
enzymes shown in red. Gray boxes represent steps where enzyme activity level was measured in isolated mitochondria. B) Aconitase activity
measured in wildtype (green) and ATP6
1 (red) mitochondria. ATP6
1 mitochondria have increased aconitase activity compared to wildtype. N=15 per
ATP6 Dysfunction and Metabolic Compensation
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Fly Strains, longevity, survival, egg laying and
development
All mutant genotypes were mt ATP6
1, sesB
1/+, wildtype controls
were mt ATP6
+, sesB/+. sesB
1 (recessive stress sensitive B mutation)
is the fly homologue to ANT (adenine nucleotide translocase)
and ATP6
1 is maintained in this mutant background and the
heteroplasmy is verified by RFLP analysis prior to experimenta-
tion (Data not shown). F1 female progeny heterozygous for sesB
1
are of high mutant heteroplasmy and were analyzed compared to
sesB
1 heterozygote controls, unless otherwise noted. Longevity was
examined as previously published [57,58,59,60,61,62,63]. Survival:
females were allowed to lay eggs in a new vial for 4 consecutive
days, each day the eggs were counted and the females were moved
to a new vial (adjustment made for unfertilized eggs). Egg laying:
genotype (0–100 ug mitochondria). Error is S.E.M. Statistical analysis is student’s t-test. C) Succinate dehydrogenase activity measured in wildtype
(green) and ATP6
1 (red) mitochondria. ATP6
1 mitochondria have reduced succinate dehydrogenase activity compared to wildtype. N=9 per
genotype. Error is S.E.M. Statistical analysis is student’s t-test.
doi:10.1371/journal.pone.0025823.g006
Figure 7. Impaired complex V dimerization and complex I supercomplex formation. A) BN-western analysis with beta and alpha subunit
antibodies reveals a marked reduction in complex V dimer (VD) relative to monomer (VM) in ATP6
1 mitochondrial isolates compared to wild type
controls. B) BN-western analysis using an antibody to complex I (NDUFS3) reveals a loss in normal supercomplexes in ATP6
1 mitochondria. C)
Quantitation of the westerns shown in panels A and B comparing WT (green) to ATP6
1 (red): dimer to monomer ratio of complex V and supercomplex
to monomer ratio of complex I.
doi:10.1371/journal.pone.0025823.g007
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intervals over a 3-day period. Development: times to transition to the
next stage was monitored every 12 hours at each temperature.
Extract preparation for HPLC assays
Animals were rapidly frozen using liquid nitrogen, weighed then
homogenized with an electric homogenizer in 200 ml 0.6 M
perchloric acid and were then neutralized by the addition of 25 ml
of 2 M potassium carbonate. Samples were centrifuged at 12,000xg
for 10 minutes at 4uC. The supernatant was then filtered through a
PVDF 0.45 mm spin column at 12,000xg for 5 minutes at 4uC.
Phosphoarginine
Arginine ratios. HPLC protocol to measure phospho-
arginine and arginine ratios was adapted from an established
method [64]. Ten ml of extract was injected. HPLC conditions:
Phenomenex Luna 5 mm NH2 25064.6 mm column and
4.663m m3mm NH2 Guard column. Flow rate of 0.6 ml/min
and detection wavelength of 205 nm. A linear mobile phase
consisting of 95:5 20 mM KH2PO4 pH 2.6: Acetonitrile.
Arginine standard was used in the linear range of 0.1–5 mM.
Phosphoarginine standard was synthesized using arginine kinase
from Homarus vulgaris longitudinal muscle similar to a published
method [65]. Retention times were 3.7 and 5.3 minutes for
arginine and phosphoarginine, respectively.
Adenylate Pool. HPLC protocol to measure ATP, ADP and
AMP levels was adapted from an established method [66]. Twenty
ml of extract was injected. HPLC conditions: Waters XBridge
Shield RP18 15064.6 mm 5 mm column and guard column. Flow
rate of 0.8 ml/min, detection wavelength of 257 nm and column
Figure 8. Model summarizing the dynamic metabolic changes resulting from ATP6 impairment compared with normal metabolism.
A) During normal metabolic activity, oxidative phosphorylation is the major producer of ATP in the cell. Glycolysis, ketogenesis and the Kreb’s cycle
contribute as needed. B) During chronic ATP6 dysfunction these less utilized pathways (glycolysis and ketogenesis) are upregulated to compensate
for the loss of oxidative phoshorylation. Complex V is unable to form a dimer and lacks ATP synthase capacity. Complex I supercomplexes are missing
and complex II activity is down, however, there is a measurable increase in aconitase activity (an additional component of the Kreb’s cycle).
doi:10.1371/journal.pone.0025823.g008
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6.5 minutes 0% B, 6.5–12.5 minutes 100% B, 12.5–25 minutes
0%B. Buffer A was 50 mM NH4H2PO4 pH 5.7, Buffer B was
60:40 Acetonitrile: H2O. ATP, ADP and AMP standards were
linear through the range of 100–250 mM. Approximate retention
times were 4.2 minutes for ATP, 4.7 minutes for ADP and 6.2
minutes for AMP.
Lactic acid levels
HPLC protocol to measure lactic acid levels was adapted from
an established method [67]. Twenty five ml of extract was injected.
HPLC conditions: Waters Atlantis dC18 15064.6 mm 3 mm
column and 4.6620 mm 3 mm Guard column. Flow rate of
0.5 ml/min, detection wavelength of 190 nm and column
temperature of 30uC. A linear mobile phase consisting of
10 mM NaH2PO4 pH 2.5. Lactic acid standard was used in the
linear range of 2–10 mM with an approximate retention time of
7.6 mintues.
Beta-hydroxybutyrate assay
Animals were cold slowed on ice before being homogenized in
10 ml PBS using a plastic pestle in a centrifuge tube. Extract was
immediately read using an Optium Xceed Meter (Abbott)
containing an Optium Plus b–ketone test strip. Readout was
given in mmol/L.
Quantitative RT-PCR. RNA was prepped using Qiagen RNAeasy
kit. Quantitative RT-PCR was performed as previously published
[60].
Respiration rate
Resting metabolic rates were measured on individual wildtype
and ATP6
1 flies at 4 ages (5, 10, 15 and 20 days post-emergence,
n=21224 animals per time point per genotype) using methods
similar to those we have previously described [68,69].
RQ measurements. To determine the relationship between
CO2 production and O2 consumption, both variables were
measured in wildtype and ATP6
1 flies at 4 ages (5, 10 and 20 days
post-emergence). Groups of 5–6 flies (n=6–9 chambers per time
point per genotype) were measured using a previously described
protocol [69].
Mitochondria isolation
A continuous percoll gradient was used to isolate mitochondria
from 1.5–2 g of wildtype or ATP6
1 adults. Protocol was adapted
from an established method [70]. Between 1.5 g and 2 g of adult
flies between the ages of 1–7 days were placed in 10 ml of cold
buffer A (250 mM sucrose, 1 mM EDTA, 50 mM Tris-HCl
pH 7.4 with protease inhibitors added before use) homogenized
and centrifuged. The supernatant was centrifuged at 10,000xg for
15 minutes and was washed. The pellet was then resuspended in
1 ml buffer B (250 mM sucrose, 1 mM EGTA, 10 mM Tris-HCl
pH 7.4), placed on top of a continuous percoll gradient (2.2 ml
2.5 M sucrose, 6.65 ml 100% percoll, 12.25 ml 10 mM Tris-HCl
pH 7.4, 84 ml 0.25 EDTA) and centrifuged at 47,000xg for 45
minutes. The mitochondria layer was removed with a syringe and
washed.
Aconitase activity. Mitosciences kit MS745 was used. Aconitase
activity is measured by following the conversion of isocitrate to cis-
aconitate through the increase of absorbance at 240 nm.
Succinate dehydrogenase activity
Protocol was adapted from an established method [71]. Activity
of sucinate dehydrogenase (U/min) was calculated as the change
of absorbance over time and multiplied by 5.18 (due to the molar
absorbance of INT-formazan).
Blue native gel electrophoresis and western analysis
Blue Native protocol was adapted from an established method
[72]. 150 mg of mitochondrial protein was loaded per well. A
gradient gel was poured with 5% acrylamide:bis-acrylamide for
the light component and 12% for the heavy component (plus
glycerol at 11.4%), a final concentration of 50 mM bis-tris and
0.5 M 6-aminohexanoic acid (APS and temed for polymerization).
Gels were run at 4uC, 50 V for 20 hours. Western analysis used
the following antibodies: complex V beta subunit (Invitrogen
A21351), complex V alpha subunit (Mitosciences MS507),
complex I NDUFS3 (Mitosciences MS112).
Seizure-like activity movie analysis
Flies were recorded using PAX-it version 6 software (Midwest
Information Systems, Inc., Villa Park, IL) through a PAXCAM
(camera) mounted on a ZEISS microscope (W.E.L. Instrument
Co). Fly movements were recorded for 5 minutes then were
treated with a strobe light (SHIMPO, Itasca, IL) at a frequency of
1450 flashes per minute for 20 seconds. After the strobe light
treatment, videotaping of the fly movements continued for an
additional 5 minutes. Video analysis was performed using iMovie
(Apple, Cupertino, CA). The recovery time was measured as the
time between the end of strobe light treatment and the first normal
fly movement (i.e. walking forward or grooming). A two-tailed
Mann-Whitney U test was used for statistical analysis at day 25
(****p,0.0001).
Statistical analysis
In all experiments standard error is represented as standard
error of the mean (S.E.M.). All analyses are student’s T-test where
the stars represent: **** p,0.0001, ***p,0.001, **p,0.01,
*p,0.05.
Supporting Information
Video S1 Video analysis of wildtype before strobe light,
demonstrating normal behavior.
(MOV)
Video S2 Video analysis of wildtype during 20 second
strobe light, demonstrating that wildtype animals do not
change their behavior during this sensory stressor.
(MOV)
Video S3 Video analysis of wildtype after strobe light,
again demonstrating that wildtype animals were unaf-
fected by the strobe light.
(MOV)
Video S4 Video analysis of ATP6
1 before strobe light,
demonstrating that ATP6
1 animals have reduced but
normal activity.
(MOV)
Video S5 Video analysis of ATP6
1 during 20 second
strobe light, demonstrating the convulsive seizure
behavior induced by the strobe light.
(MOV)
Video S6 Video analysis of ATP6
1 after strobe light,
some ATP6
1 animals continue convulsive seizure behav-
ior while others exhibit paralysis.
(MOV)
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